Monepantel, a veterinary drug that PharmAust is repurposing for amyotrophic lateral sclerosis (ALS), continues to slow disease progression and extend survival when taken daily for up to nearly two years, while being generally well tolerated by patients. That’s according to interim results from an open-label extension…
Two U.S. representatives have introduced legislation that would establish a federally funded research program to study the link between environmental factors and amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The Harmonizing Environmental Analyses and Launching Therapeutic Hubs to Yield Bolstered Research and Innovation in Neurological Science (Healthy…
My daughter, Sara, is beginning her freshman year at a university a couple hours from us, and last Saturday was her day to move into the dorms. I had planned to help her move, so weeks ago I lined up a daytime caregiver for my husband, Todd, who has…
Targeting two particular proteins, called H1.2 and PARP1, may lessen the severity of amyotrophic lateral sclerosis (ALS) linked to mutations in the FUS gene, a study shows. Researchers found that a severe FUS mutation increased the interaction of the resulting FUS protein with both H1.2 and PARP1, which is involved in…
Dewpoint Therapeutics has won a second grant from Target ALS Foundation to advance preclinical studies of its experimental TDP-43-targeted therapy for amyotrophic lateral sclerosis (ALS). TDP-43 is a protein that often gets mislocalized within cells in ALS and forms into toxic clumps that contribute to neurodegeneration. Dewpoint’s…
A consortium of amyotrophic lateral sclerosis (ALS) nonprofits and industry stakeholders has launched Project Mosaic, an initiative that aims to advance next-generation, patient-derived cell models that more accurately represent ALS’ complex and diverse nature. By moving these ALS models from academic labs to industry, Project Mosaic aims to…
Among the many challenges I experienced during my early months with ALS was the eerie prophecy of a life expectancy of two to five years following diagnosis. Besides putting the brakes on all of my future hopes and dreams, it made my brain feel worthless. I’d ask myself,…
Two amyotrophic lateral sclerosis (ALS) centers are backing an initiative aimed at accelerating and improving ALS research. The Acceleration Centers of Enrollment (ACE) initiative, led by the Les Turner ALS Center at Northwestern Medicine and the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital, will…
The Muscular Dystrophy Association (MDA) is accepting applications for its Advocacy Collaboration Grant program, which supports projects from organizations working to improve the lives of people with neuromuscular diseases such as amyotrophic lateral sclerosis (ALS). Applications for this year’s program are open until Oct. 18, and…
The Muscular Dystrophy Association (MDA) and the International Association of Fire Fighters (IAFF) are teaming up once again, launching more than 420 “Fill the Boot” events this year to raise funds for research and care for people with neuromuscular diseases, including amyotrophic lateral sclerosis (ALS). The fundraising initiative will…
Get regular updates to your inbox.